Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts This week, 27 April 2025: Treatment-resistant hypertension Influenza transmission Nanoplastics in human brains Malaria elimination Chikungunya vaccine

Prostate Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 26 articles: HTML format

Single Articles

February 2025
1. SEKAR RR, Zebib L, Stensland KD, Herrel LA, et al
   Structural inequities in the availability of prostate cancer clinical trial opportunities.
   J Natl Cancer Inst. 2025 Feb 26:djaf047. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2025
2. TOSOIAN JJ
   Active surveillance for prostate cancer: How active is too active?
   J Natl Cancer Inst. 2025 Jan 27:djae342. doi: 10.1093.
   PubMed    
   
   
   
3. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
   NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
   J Natl Cancer Inst. 2025;117:120-133.
   PubMed     Abstract available
   
   
   
4. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
   Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
   J Natl Cancer Inst. 2025;117:188-197.
   PubMed     Abstract available
   
   
   November 2024
5. HAMMARLUND N, Holt SK, Etzioni R, Morehead D, et al
   The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.
   J Natl Cancer Inst. 2024 Nov 20:djae302. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. ZHAO Y, Gulati R, Yang Z, Newcomb L, et al
   Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
   J Natl Cancer Inst. 2024 Nov 20:djae296. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2024
7. COOPERBERG MR, Braun AE, Berlin A, Kibel AS, et al
   When is prostate cancer really cancer?
   J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
   Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
   J Natl Cancer Inst. 2024;116:1675-1682.
   PubMed     Abstract available
   
   
   
9. LIU S, Rivero SL, Zhang B, Shen K, et al
   BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression.
   J Natl Cancer Inst. 2024;116:1598-1611.
   PubMed     Abstract available
   
   
   September 2024
10. EL KHOURY CJ, Freedland SJ, Gandhi K, Keith SW, et al
    Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study.
    J Natl Cancer Inst. 2024 Sep 23:djae234. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
11. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    July 2024
12. FARAJ KS, Oerline M, Kaufman SR, Dall C, et al
    Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.
    J Natl Cancer Inst. 2024 Jul 25:djae155. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
13. DING CC, Tony Su Z, Erak E, DePaula Oliveira L, et al
    Predicting prostate cancer grade reclassification on active surveillance using a deep Learning-Based grading algorithm.
    J Natl Cancer Inst. 2024 Jun 18:djae139. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
14. BJORNEBO L, Razdan S, Discacciati A, Palsdottir T, et al
    Prostate Cancer Incidence and Mortality in Men Exposed to alpha1-Adrenoceptor Antagonists.
    J Natl Cancer Inst. 2024 May 8:djae108. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
15. BASU A, Rais-Bahrami S
    Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
    J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093.
    PubMed    
    
    
    
16. LAO Y, Guan X, Wang J, Bai Y, et al
    RE: Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study.
    J Natl Cancer Inst. 2024 Feb 12:djae032. doi: 10.1093.
    PubMed    
    
    
    January 2024
17. LEE KM, Nelson T, Bryant A, Teerlink C, et al
    Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
    J Natl Cancer Inst. 2024 Jan 11:djae002. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. WILKINSON S, Sowalsky AG
    Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.
    J Natl Cancer Inst. 2024;116:12-14.
    PubMed    
    
    
    
19. FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al
    Changes in cancer-related mortality during the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2024;116:167-169.
    PubMed     Abstract available
    
    
    December 2023
20. CRUMP C, Stattin P, Brooks JD, Sundquist J, et al
    Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study.
    J Natl Cancer Inst. 2023 Dec 7:djad257. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
21. FREEMAN JR, Saint-Maurice PF, Watts EL, Moore SC, et al
    Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.
    J Natl Cancer Inst. 2023 Nov 28:djad210. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. COOPERBERG MR
    Can early prostate cancer screening help address mortality disparities among Black men?
    J Natl Cancer Inst. 2023 Nov 10:djad217. doi: 10.1093.
    PubMed    
    
    
    October 2023
23. HU S, Chang CP, Snyder J, Deshmukh V, et al
    Mental health outcomes in a population-based cohort of patients with prostate cancer.
    J Natl Cancer Inst. 2023 Oct 23:djad175. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. MA T, Jin L, Bai S, Liu Z, et al
    Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate Cancer Progression.
    J Natl Cancer Inst. 2023 Oct 17:djad215. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
25. KENSLER KH, Johnson R, Morley F, Albrair M, et al
    Prostate Cancer Screening in African American Men: A Review of the Evidence.
    J Natl Cancer Inst. 2023 Sep 15:djad193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. SUMIYOSHI T, Wang X, Warner EW, Sboner A, et al
    Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.
    J Natl Cancer Inst. 2023 Sep 7:djad184. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.